BOBS
Bob's Discount Furniture, Inc.
BOBS has the edge over LCID overall, supported by stronger modeled upside.
LCID
Lucid Group, Inc.
LCID has slightly lower modeled downside risk, despite its lower overall score.
BOBS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Strong |
BOBS's revenue, profitability, cash flow and balance sheet are all currently healthy.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
BOBS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $15.74 | -24% |
| Fair | 17x | $18.59 | -9.9% |
| Expensive | 19x | $20.33 | -1.5% |
| Current | 19x | $20.64 | — |
Historical ranges are pointers, not guarantees.
BOBS's PE is 19x, but its earnings don't support one, so it isn't a reliable read right now.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
BOBS Forward outlook
There aren't enough analyst estimates for BOBS to show an outlook.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
BOBS Earnings Per Share
BOBS and LCID do not have enough comparable growth data to identify a winner.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
BOBS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $680.4M | +10% |
| Q2 2026 | $619.6M | +8.8% |
| Q1 2026 | $578.1M | +8.5% |
| Q4 2025 | $648.8M | +8.2% |
BOBS's revenue has grown year over year every quarter since late 2025: $680M last quarter, up 10% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 8.7% | +0.3 points |
| Q2 2026 | 13% | +4 points |
| Q1 2026 | 3% | -0.9 points |
| Q4 2025 | 9.2% | N/A |
| Q3 2025 | 8.3% | -1 points |
| Q2 2025 | 8.7% | N/A |
| Q1 2025 | 3.9% | N/A |
| Q4 2024 | 9.3% | N/A |
BOBS has the edge over LCID on profitability, with a higher operating margin.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over BOBS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
BOBS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $81.3M | +30% |
| Q2 2026 | $36M | +248% |
| Q1 2026 | -$2.7M | +$9.4M |
| Q4 2025 | $20.7M | -60% |
BOBS has the edge over LCID on cash generation, producing positive trailing cash flow while its opponent burns cash.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
BOBS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +586K shares |
| 1 year | +4.5% | +5.9M shares |
BOBS has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $50,000 |
| Q4 2025 | $17,000 |
| Q3 2025 | $401,000 |
| Q2 2025 | $626,000 |
| Q1 2025 | $83,000 |
| Q4 2024 | $358,000 |
BOBS has spent almost nothing on buybacks in the past year.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
BOBS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.4x | Net Cash |
| Q2 2026 | -0.1x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | 1.4x | Healthy |
BOBS has more cash than debt.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
BOBS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 71.2 | Overbought |
| Stochastic | 78.2 | Neutral |
BOBS's weekly RSI is 71 (overbought) and its Stochastic is 78 (neutral).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
BOBS PE vs Consumer Cyclical Sector
| Metric | BOBS | Sector median | Relative |
|---|---|---|---|
| PE | 19x | 18x | 6% above |
| PE % | 95 | 13 | 82 pts above |
BOBS is trading at 19x earnings, in line with the Consumer Cyclical sector's median of 18x, though its earnings don't support one.
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
BOBS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $16.2 | 27% above |
| 20 week MA | $16.5 | 25% above |
BOBS has stronger trend alignment. BOBS is above 2 of 2 weekly averages versus LCID above 0 of 5.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
BOBS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2026 YTD | $16.5 | $20.6 | +25% |
BOBS has the edge over LCID on returns for 2026, with the stronger performance.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.